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Abstract
Background: Appropriate patient selection is needed for targeted therapies that are efficacious only in patients with
specific genetic alterations. We aimed to define subgroups of patients with candidate driver genes in patients with non-
small cell lung cancer.
Methods: Patients with primary lung cancer who underwent clinical genetic tests at Guangdong General Hospital were
enrolled. Driver genes were detected by sequencing, high-resolution melt analysis, qPCR, or multiple PCR and RACE
methods.
Results: 524 patients were enrolled in this study, and the differences in driver gene alterations among subgroups were
analyzed based on histology and smoking status. In a subgroup of non-smokers with adenocarcinoma, EGFR was the most
frequently altered gene, with a mutation rate of 49.8%, followed by EML4-ALK (9.3%), PTEN (9.1%), PIK3CA (5.2%), c-Met
(4.8%), KRAS (4.5%), STK11 (2.7%), and BRAF (1.9%). The three most frequently altered genes in a subgroup of smokers with
adenocarcinoma were EGFR (22.0%), STK11 (19.0%), and KRAS (12.0%). We only found EGFR (8.0%), c-Met (2.8%), and PIK3CA
(2.6%) alterations in the non-smoker with squamous cell carcinoma (SCC) subgroup. PTEN (16.1%), STK11 (8.3%), and PIK3CA
(7.2%) were the three most frequently enriched genes in smokers with SCC. DDR2 and FGFR2 only presented in smokers
with SCC (4.4% and 2.2%, respectively). Among these four subgroups, the differences in EGFR, KRAS, and PTEN mutations
were statistically significant.
Conclusion: The distinct features of driver gene alterations in different subgroups based on histology and smoking status
were helpful in defining patients for future clinical trials that target these genes. This study also suggests that we may
consider patients with infrequent alterations of driver genes as having rare or orphan diseases that should be managed with
special molecularly targeted therapies.
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Introduction
Lung cancer is a leading cause of cancer death in both men and
women in the United States and throughout the world. Although
various chemotherapeutic agents were developed in the late 1980s
and1990s,treatmentssuchasplatinumdoublettherapyseemtohave
reachedatherapeuticplateau,withanobjectiveresponserateof30–
40%andamediansurvivaltimeofapproximately1yearforpatients
withstageIIIBorstageIVdisease[1].Tofurtherimprovetreatment
outcomes,newstrategiestargetingmoleculargenomicabnormalities
are under intensiveinvestigation.
Several molecular alterations are known to occur in genes that
encode signaling proteins critical for cellular proliferation and
survival. These genes have been defined as ‘‘driver genes’’. In lung
adenocarcinoma, such driver genes include epidermal growth
factor receptor (EGFR), KRAS, BRAF, PIK3CA, and EML4-
ALK. Mutations in these genes are responsible for both the
initiation and maintenance of malignancy [2,3]. Other driver
genes have been more recently defined, including STL11 (also
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e40109known as LKB1), PTEN, DDR2, and FGFR2 [4–8]. By
understanding the functions of these driver genes, it may be
possible to develop specific therapies for malignancies with known
driver gene mutations.
Tyrosine kinase inhibitors (TKI) targeting EGFR, including
gefitinib and erlotinib, have become the standard first line therapy
for patients with advanced non-small cell lung cancer (NSCLC)
that harbor activating EGFR mutations [9,10]. However, almost
all patients eventually develop resistance to EGFR TKIs. A
number of mechanisms of resistance including KRAS mutation,
EGFR exon 20 T790M mutation, and MET gene amplification,
have been reported. Thus, a comprehensive molecular profile is
needed to understand both the sensitivity and resistance to
molecular targeted therapy for lung cancer [11].
Given the importance of biomarker selection to targeted cancer
therapies, our group initiated the Guangdong General Hospital
Lung Cancer Mutation Project (GGHLCMP). The objective of
this project is to explore the impact of tobacco consumption and
histology type on the incidence of driver gene mutations and to
define subgroups of patients in whom candidate driver gene
alterations are enriched. Here we report on a spectrum of driver
genes, including EGFR, KRAS, c-Met, PIK3CA, BRAF, STK11,
PTEN, EML4-ALK fusion gene, DDR2, and FGFR2 in a
population of Chinese patients with primary lung cancer.
Methods
Ethics Statement and Patient Selection
A total of 1800 patients were referred to Guangdong General
Hospital (GGH) for genomic studies between January 2007 and
December 2009 (Figure 1). Eligibility criteria included the
following: histologic diagnosis of primary lung cancer; availability
of demographic data, including age, gender, smoking status,
histology and disease stage; availability of survival data; availability
of tumor samples for genomic analyses; and provision of informed
consent. Lung cancer diagnosis was confirmed by an independent
pathologist. Clinical data were collected from the case histories of
the patients in the hospital. Non-smokers were defined as patients
who had smoked ,100 cigarettes in their lifetime; smokers
included former and current smokers. Patients with other
malignancies or benign lung tumors were excluded. The study
was approved by the ethics committee of Guangdong General
Hospital. All patients provided written informed consent.
Gene Alterations Detection
Tumor tissues biopsies were snap frozen in liquid nitrogen and
stored at 270uC until analysis. We evaluated the tissues before
genetic detection using HE staining. Specimens with $50% tumor
cells were enrolled into this study. 357 samples were obtained from
tumor specimens resected and 167 samples were from core
biopsies. DNA and RNA were extracted by the Aqua-SPIN
Tissue/Cell gDNA Isolation Mini Kit (Biowatson, Shanghai,
China) and RNeasy Mini Kit (Qiagen, Valencia, CA), respectively.
The integrity and quantity of RNA and DNA were assessed by gel
electrophoresis and Thermo Manodrap 1000 (Thermo, MA, USA)
analysis. cDNA was synthesized using an ABI High-Capacity
cDNA Reverse Transcription Kit with RNase Inhibitor (ABI, CA,
USA). Mutations in EGFR and KRAS were detected by PCR-
based sequencing [12]. PIK3CA and BRAF mutations were
detected by high-resolution DNA melting analysis [13]. EML4-
ALK mutations were analyzed by multiple PCR and RACE on
cDNA [14]. c-Met amplification was determined by qPCR on
DNA [15]. PTEN (cDNA), STK11(cDNA), DDR2, and FGFR2
(DNA) mutations were detected by PCR-based sequencing (Table
S1). All testing procedures were previously described in the
references.
Statistical Analysis
Alterations between different subgroups stratified by histology
and smoking status were analyzed by Chi-square and Fisher’s
exact tests when appropriate. Survival analysis was performed by
Kaplan-Meier analysis with a log-rank test. Multivariate analyses
were conducted using Cox’s proportional hazards model (For-
ward: Wald; P=0.05, entry; P=0.10, Removal). All p values were
two-sided, and P,0.05 was assumed to be significant.
Results
Patient Characteristics
A total of 524 eligible patients were enrolled; the patient
characteristics are summarized in Table 1. The male to female
ratio was 2.2:1. The mean patient age was 59.3 years old, ranging
from 23 to 88 years old. A total of 292 patients were never-smokers
(55.7%) There were more patients with adenocarcinoma (67.6%)
than squamous cell carcinoma (27.5%). Early stage resectable lung
cancer accounted for 41% of the study population. Survival
outcome data were cut off on August 1, 2011, and a total of 138
death events occurred.
Incidence of Driver Genes
Mutations in exons 18–21 for EGFR, exons 9 and 20 for
PIK3CA, exons 11 and 15 for BRAF, exons 1–9 for of PTEN,
codons 12, 13, 59, and 60 for KRAS, exons 6, 9,14, 16, and 18 for
DDR2, exons 6, 7 and 14 for FGFR2, exons 1–5 for STK11, and
variations of EML4-ALK fusion were detected (representative
graphs are indicated in Figures S1, S2, S3, S4, and S5). The cut-off
point for c-Met high-level amplifications was defined as the
mean+5SD of the control group as described previously [15].
Because more than 23 tests were performed for the genes in this
study, some specimens were not available in sufficient amounts for
all tests to be performed. The details of each gene in every
subgroup can be found in the table of frequency of driver gene
alterations. The alteration rates of the genes in the subgroups were
calculated as positive/detected samples. The mutation rate of
EGFR in NSCLC was 28.4% (147/517), PTEN was 9.5% (21/
220), STK11 was 7.9%(8/101), EML4-ALK was 6.3% (15/239),
KRAS was 5.4% (27/498), c-Met was 4.5% (20/448), PIK3CA
was 4.4% (20/452), BRAF was 1.5% (7/452), DDR2 was 1.2%
(2/166), and FGFR2 was 0.6% (1/165), respectively. The
mutation characteristics of these genes were shown in table 2.
We found 5 patients with concurrent EGFR exon 21 L858R and
exon 20 mutation, and 3 patients with concurrent EGFR exon 21
L858R and exon 19 deletion (Figure 2).
A number of patients were found to have multiple driver gene
alterations (Table 3). A total of 23 patients with EGFR mutations
had c-MET amplifications or mutations of STK11, PIK3CA,
BRAF or PTEN. Of particular interest, one patient with EML4-
ALK fusion had an activating EGFR mutation, and another
patient had a PTEN mutation. Other common dual mutations
occurred in patients with BRAF and KRAS, or BRAF and
PIK3CA mutations. Only one patient had a triple mutation of
EGFR, PIK3CA, and BRAF. EGFR and KRAS, PTEN and
KRAS, PIK3CA and PTEN are mutually exclusive in this study.
Smoking Status is Associated with Driver Gene
Alterations
We analyzed relationships between driver genes and smoking
status (Table 4). EGFR mutation rates were significantly higher in
Driver Genes in NSCLC
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X
2=50.791, P,0.0005, chi-squared test, 2-sided]. KRAS muta-
tion rates were significantly lower in non-smokers than smokers
[3.6% (10/279) vs. 7.8% (17/219), X
2=4.177, P=0.041]. STK11
and PTEN mutations in non-smokers were lower than in smokers,
but the difference was of marginal significance [2.1% (1/48) and
6.3% (7/112) vs. 13.2% (7/53) and 13.0% (14/108), X
2=4.274
and 2.87, P=0.062 and 0.09, respectively]. DDR2 and FGFR2
mutations were found to be present only in smokers, but no
significant differences were found. c-Met, PIK3CA, BRAF, and
ALK mutations were not found to be related to smoking status.
Different Histology Types are Associated with Different
Driver Genes
We analyzed differences in driver gene mutations among
different histology subtypes (Table 4). The mutation rates of
EGFR in adenocarcinoma (AC), squamous cell carcinoma (SCC),
and large cell carcinoma (LCC) were 40.3% (140/347), 4.4% (6/
144), and 3.8% (1/26), respectively (X
2=73.595, P,0.0005, Chi-
square test, 2-sided). KRAS mutation rates in AC, SCC, and LCC
were 7.1% (24/340), 1.5% (2/132), and 3.8% (1/26), respectively
(X
2=6.124, P=0.039, Fisher’s exact test,). PTEN mutation rates
in AC, SCC, and LCC were 7.0% (8/115), 10.6% (10/94), and
27.3% (3/11), respectively (X
2=4.642, P=0.084, Fisher’s exact
test). BRAF mutations were found only in AC; DDR2 and FGFR2
Figure 1. Study design and key procedures.
doi:10.1371/journal.pone.0040109.g001
Table 1. Characteristics of the patients in this study.
Variable Group No. (%)
Sex Male 361(68.9)
Female 163(31.1)
Age (years) Mean 59.3
Range 23–88
Cigarette smoking No 292(55.7)
Yes 232(44.3)
Histological status AC 354(67.6)
SCC 144(27.5)
LCC 26(4.9)
Stage I 143(27.3)
II 72(13.7)
III 135(25.8)
IV 174(33.2)
Follow-up status Survival 386(73.7)
Death 138(26.3)
Total 524(100)
doi:10.1371/journal.pone.0040109.t001
Figure 2. EGFR mutation rate in TK domain (N=147). Exon
20+21, mutations of exon 20 and exon 21 concurrently presented in the
same patients; Exon19+21, mutations of exon 19 and exon 21
concurrently presented in the same patients.
doi:10.1371/journal.pone.0040109.g002
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were found. The differences of c-Met high-level amplifications,
PIK3CA and STK11 mutations, and EML4-ALK fusions in
patients with different histologic types did not reach statistical
significance. Overlaps of these alterations mainly presented in
patients with AC, and only 2 patients with SCC and 2 patients
with LCC.
Distinct diseases classified by driver genes based on histology
combined with smoking status.
We performed further stratification analyses based on
histologic types (AC and SCC) and smoking status together.
The patients were classified into four subgroups (Figure 3,
Table 4). In the AC non-smoker subgroup, EGFR was the most
frequently altered gene (49.8%, 114/229), followed by EML4-
ALK fusion (9.3%, 8/86), then PTEN mutation (9.1%, 7/77),
PIK3CA mutation (5.2%, 11/210), c-Met amplification (4.8%,
10/207), KRAS mutation (4.5%, 10/223), STK11 mutation
(2.7%, 1/37), BRAF mutation (1.9%, 4/210), DDR2 mutation
Table 2. Mutation characteristics of these genes.
Gene Exon/domain N Main activated mutation or aminoacid changes
EGFR Total 147
Exon 18 3 G719A, G719V, G719D
Exon 19 68 E746–A750 del, E746–S752 del, L747–A750 (751, 753) del
Exon 20 11 T790M, R776H
Exon 21 57 L858R, L858M, L861R
Exon 19+21 3 Concurrent with exon 19 deletion and exon 21 L858R
Exon 20+21 5 Concurrent with exon 20 T790M and L858R, R776H and L858R
STK11 Exon 1–5 8 M125–Y126 del, S59 del, S69X, L9–S213 del
PTEN Exon 1–9 21 C71F, N91K, Q298X, Y68H
KRAS Total 27
Codon 12 27 12 with G12C, 5 with G12V, 5 with G12D, and 5 with others
PIK3CA Total 20
Exon 9 13
Exon 20 6
Exon 9+20 1 1 with concurrent exon 9 and 20 mutation
BRAF Total 7
Exon 11 4
Exon 15 3
DDR2 Total 2
Exon 6 1 M117V
Exon 16 1 R680L
FGFR2 Total 1
Exon 7 1 P303R
No activated mutations were found in codon 13, 59, and 60 of KRAS, in exon 9 and 14 of DDR2, and in exon 6 and 4 of FGFR2 gene.
doi:10.1371/journal.pone.0040109.t002
Table 3. Overlaps of the alterations of these driver genes.
Gene Total EGFR STK11 KRAS c-Met PIK3CA BRAF PTEN ALK DDR2
EGFR 28.4%(147/517)
STK11 8.9%(9/101) 1
KRAS 5.4%(27/498) 0 0
c-Met 4.5%(20/448) 7 0 1
PIK3CA 4.4%(20/452) 7010
BRAF 1.5%(7/452) 2010 2
PTEN 9.5%(21/220) 6101 00
ALK 6.3%(15/239) 1100 00 1
DDR2 1.2%(2/166) 0000 00 0 0
F G F R 2 0 . 6 % ( 1 / 1 6 5 ) 0000 00 0 0 0
doi:10.1371/journal.pone.0040109.t003
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smoker subgroup, the most enriched gene was also EGFR
mutation (22.0%, 26/118), followed by STK11 mutation
(19.0%, 4/21), then KRAS mutation (12.0%, 14/117), EML4-
ALK fusion (4.5%, 2/44), c-Met amplification (4.0%, 4/101),
BRAF mutation (3.1%, 3/97), PTEN mutation (2.6%, 1/38),
and PIK3CA (2.1%, 2/97). We only found EGFR (8.0%, 4/50),
c-Met (2.8%, 1/36), and PIK3CA (2.6%, 1/38) alterations in
the non-smoker with SCC subgroup. In the smoker with SCC
group, the most frequently enriched genes were PTEN
mutations (16.1%, 10/62), followed by STK11 mutation
(8.3%, 2/24), then PIK3CA mutation (7.2%, 6/83), EML4-
ALK fusion (6.5%, 4/62), c-Met amplification (6.3%, 5/80),
DDR2 mutation (4.4%, 2/45), KRAS mutation (2.3%, 2/88),
FRFR2 mutation (2.2%, 1/45), EGFR mutation (2.1%, 2/94),
and BRAF (0%, 0/94). Among these four subgroups, the
differences in EGFR, KRAS, and PTEN mutations were
statistically significant (X
2=92.991, 11.951, 8.628. P=0.0005,
0.005, and 0.023, respectively, chi-squared test or Fisher’s exact
test when appropriate). DDR2 and FGFR2 mutations only
presented in the SCC smoker subgroup. The unknown variation
rate of the patients in the non-smoker SCC subgroup was
approximately 86.6, which was the highest of these four
subgroups. Survival analysis based on the four subgroups did
not reveal any differences between the subgroups (Figure 3).
Survival Analysis of Patients with Differing Driver Gene
Features
Based on EGFR mutations, we classified patients into two
subgroups for survival analysis; EGFR mutation positive and
negative group. No difference in survival time was found between
the two subgroups for the total EGFR mutation detected patient
population (X
2=0.957, P=0.328. Figure 4). Multivariable analysis
of Cox Regression including the EGFR mutation, stage, histology,
gender, smoking status, and age indicated that only the stage was
the independent prognostic factor of the patients (X
2=16.607,
P,0.0005, Forward: Wald; P=0.05, entry; P=0.10, Removal).
We performed further stratification analysis based on the clinical
stages of the patients. For stage 1 patients, the patients with EGFR
mutation positive had longer survival time than patients with
EGFR negative (X
2=3.947, P=0.047, Figure 4).
Discussion
To our knowledge, this is the first study to investigate an entire
profile of both the best known as well as novel driver genes, such as
PTEN, DDR2, and FGFR2, in NSCLC patients, while taking into
account different histologic types and smoking status in Chinese
lung cancer patients. Different studies on driver genes may obtain
differing results due to the ethnicity or clinical information of the
patients [16–22]. The large sample size and the complex makeup
of our patient population allowed us to compare differences
among patient subgroups. The majority of previously published
studies investigating driver genes have only focused on a specific
subgroup of patients with AC or non-smokers [3,15,21]. The Lung
Cancer Mutation Consortium sponsored by NCI is also interested
in patients with adenocarcinoma [23]. The management of
NSCLC is currently moving from a standard of care based on
stage and performance status to more individualized therapies
based on clinical, histologic, and molecular factors [24]. Accord-
ingly, our study provides the first clear picture of how driver genes
in an NSCLC population can vary with tumor histology and
smoking status and finds subgroups of patients in whom alterations
in these candidate genes are most enriched; these genes may
therefore be targeted for individualized therapies. Furthermore,
we analyzed the impact of driver gene alterations on the overall
survival of patients.
The specific features of driver genes associated with each
subgroup suggest that these subgroups might in fact be different
diseases that will, in future, require different targeted therapies.
Epidemiological, molecular and clinical-pathological features have
shown that NSCLC in never smokers is a distinct entity [25]. Our
subgroup analysis of NSCLC based on histology and smoking
status showed that histology and smoking status could significantly
influence alterations of driver genes, especially for EGFR, KRAS,
STK11 and PTEN. EGFR mutations were enriched in non-
smoker patients with AC, KRAS in smokers with AC, and STK11
and PTEN in smokers. Although a subtype of non-smoker patients
with AC has been intensively investigated due to their sensitivity to
Table 4. Frequency of driver gene alterations in different subgroups.
Group EGFR PTEN STK11 ALK KRAS c-Met PIK3CA BRAF DDR2 FGFR2
NSCLC 28.4%(147/517) 9.5%(21/220) 7.9%(8/101) 6.3%(15/
239)
5.4%(27/498) 4.5%(20/448) 4.4%(20/452) 1.5%(7/452) 1.2%(2/166) 0.6%(1/165)
Non-smoker 40.9%(119/291) 6.3%(7/112) 2.1%(1/48) 6.4%(8/
125)
3.6%(10/279) 4.3%(11/255) 4.6%(12/260) 1.5%(4/260) 0%(0/91) 0%(0/90)
Smokers 12.4%(28/226) 13.0%(14/108) 13.2%(7/53) 6.1%(7/
114)
7.8%(17/219) 4.7%(9/193) 4.2%(8/192) 1.6%(3/192) 2.7%(2/75) 1.3%(1/75)
AC 40.3%(140/347) 7.0%(8/115) 8.6%(5/58) 7.7%(10/
130)
7.1%(24/340) 4.5%(14/308) 4.2%(13/307) 2.3%(7/307) 0%(0/97) 0%(0/96)
SCC 4.4%(6/144) 10.6%(10/94) 6.1%(2/33) 4.1%(4/93) 1.5%(2/132) 5.2%(6/116) 5.8%(7/121) 0.0%(0/121) 3.3%(2/61) 1.6%(1/61)
LCC 3.8%(1/26) 27.3%(3/11) 10.0%(1/10) 8.3%(1/12) 3.8%(1/26) 0.0%(0/24) 0.0%(0/24) 0.0%(0/24) 0%(0/8) 0%(0/8)
NS with AC 49.8%(114/229) 9.1%(7/77) 2.7%(1/37) 9.3%(8/86) 4.5%(10/223) 4.8%(10/207) 5.2%(11/210) 1.9%(4/210) 0.0%(0/71) 0.0%(0/70)
S with AC 22.0%(26/118) 2.6%(1/38) 19.0%(4/21) 4.5%(2/44) 12.0%(14/117) 4.0%(4/101) 2.1%(2/97) 3.1%(3/97) 0.0%(0/26) 0.0%(0/26)
NS with SCC 8.0%(4/50) 0.0%(0/32) 0.0%(0/9) 0.0%(0/35) 0.0%(0/44) 2.8%(1/36) 2.6%(1/38) 0.0%(0/38) 0.0%(0/16) 0.0%(0/16)
S with SCC 2.1%(2/94) 16.1%(10/62) 8.3%(2/24) 6.5%(4/62) 2.3%(2/88) 6.3%(5/80) 7.2%(6/83) 0%(0/94) 4.4%(2/45) 2.2%(1/45)
NSCLC: non-small cell lung cancer; NS with AC: patients with adenocarcinoma in non-smokers; S with AC: patients with adenocarcinoma in smokers; NS with SCC:
patients with squamous cell carcinoma in non-smokers; S with SCC: patients with squamous cell carcinoma in smokers.
doi:10.1371/journal.pone.0040109.t004
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studied. Our study revealed that mutations of KRAS and BRAF in
smoker AC patients were the highest among these subtypes. This
study also indicates that non-smoker patients with SCC had the
highest unknown alterations among the four subgroups. No
alterations of KRAS, BRAF, PTEN, ALK, DDR2, and FGFR2
were found in non-smoker patients with SCC subgroup. The
alteration rates of EGFR, c-Met, and PIK3CA were slightly lower
among these subtypes. This demonstrates that non-smoker
patients with SCC may have pathogenic mechanisms that different
from known driver gene alterations. This study also revealed that a
subtype of smokers with SCC had special characteristics as DDR2
and FGFR2 only presented in this subgroup. With the exception
of BRAF, which only presented in AC, all of the other genes can
be found in a subtype of smokers with SCC. PIK3CA mutations
and c-Met amplification rates in smokers with SCC subtype were
the highest among this subtype. Although our LCC sample size
was small, we found that the PTEN mutation rate (27.3%) in LCC
was the highest among all the subtypes. Emerging data reveals that
tumor histology may relate to the benefits of specific chemother-
apies or targeted therapy regimens [24]. Such relationships may
also be partially associated with driver gene differences. The make-
up of these genes in different subtypes may therefore be helpful to
define specific variations of driver genes that could considerably
refine treatment of NSCLC [26].
Our results indicate that all other genes are infrequently altered
(,10%) in Chinese NSCLC patients, except EGFR mutations
(28.4%). Driver mutations occur in genes that encode signaling
Figure 3. Rates of driver gene variations and survival analysis in patients with different histologic type and smoking status. (a),
Survival analysis of subgroups, (b) Rates of driver gene variations of subgroups. NS with AC: patients with adenocarcinoma in non-smokers, S with AC:
patients with adenocarcinoma in smokers, NS with SCC: patients with squamous cell carcinoma in non-smokers, S with SCC: patients with squamous
cell carcinoma in smokers.
doi:10.1371/journal.pone.0040109.g003
Figure 4. Survival analysis of driver genes. (a), Survival analysis of all of the EGFR detected patients; (b), Survival analysis of the stage I patients.
NR: not reached.
doi:10.1371/journal.pone.0040109.g004
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Together with our findings, this implies that a new classification
method for NSCLC patients may be proposed based on the
molecular biomarkers. Patients with infrequent alterations of
driver genes could be considered to have rare or orphan diseases
and should be considered different, from a research and
individualized therapy point of view and in the future. A subgroup
analysis of these driver genes in our study was very helpful for
defining patients with different driver gene alterations for further
clinical trials.
The alteration of some driver genes have a little difference from
published studies, that may due to the different population studied
[20,21]. The study reported that mutations in EGFR and KRAS
were observed in 7 (7%) and 36 (38%) patients, respectively [22].
Others reported that KRAS mutations were detected in 75 of 395
(19%) and 40 of 233 (17%) patients with NSCLC, respectively
[16,17]. Interestingly, though the KRAS mutation rate is different,
but the preference of patients is the same, that is mutation appears
to be more frequent in smokers and AC, current or former
smokers had a higher frequency of KRAS mutations than never
smokers [18,19].
Overlap mutations of driver genes revealed the complexity of
individualized therapy in lung cancer in the future. EGFR and
KRAS were the two most important genes studied by many
researchers. Our study found EGFR mutation could overlap with
the other detected genes except KRAS, DDR2 and FGFR2. RAS
and several of its downstream effectors, including BRAF, have
since been shown to be commonly mutated in broad range of
human cancers and biological studies have confirmed that RAS
pathway activation promotes tumor initiation, progression and
metastatic spread in many contexts [28]. Though in our study
BRAF mutation rate in NSCLC is infrequent 1.5% (7/452), 2 of
the 7 patients harbored concurrent EGFR and BRAF mutations.
This is different from the reported that BRAF mutations are
mutually exclusive to EGFR and KRAS mutations [29,30]. ALK
was found in 1 patient with AC to be concurrent presented with
EGFR mutation. That’s different with the previous reported
results that the EML4-ALK fusions were mutually exclusive with
mutations in the EGFR gene [31,32]. We believe that more and
more overlaps of driver genes will be reported in the future, so the
clinical practice will not only need to consider the sensitive
mutation, but also need to consider the resistance mutation in the
same patients for the same target therapy or combined therapy.
Overlap mutations of driver genes revealed the complexity of
individualized therapy in lung cancer in the future. EGFR and
KRAS were the two most important genes studied by many
researchers. Our study found EGFR mutation could overlap with
the other detected genes except KRAS, DDR2 and FGFR2. RAS
and several of its downstream effectors, including BRAF, have
since been shown to be commonly mutated in broad range of
human cancers and biological studies have confirmed that RAS
pathway activation promotes tumor initiation, progression and
metastatic spread in many contexts [27]. Though in our study
BRAF mutation rate in NSCLC is infrequent 1.5% (7/452), 2 of
the 7 patients harbored concurrent EGFR and BRAF mutations.
This is different from the reported that BRAF mutations are
mutually exclusive to EGFR and KRAS mutations [28,29]. ALK
was found in 1 patient with AC to be concurrent presented with
EGFR mutation. That’s different with the previous reported
results that the EML4-ALK fusions were mutually exclusive with
mutations in the EGFR gene [30,31]. We believe that more and
more overlaps of driver genes will be reported in the future, so the
clinical practice will not only need to consider the sensitive
mutation, but also need to consider the resistance mutation in the
same patients for the same target therapy or combined therapy.
We analyzed the prognostic significance of these subgroups and
driver gene alterations. We did not find any differences in overall
survival among these subgroups based on histology and smoking
status. Our study and other study indicated that EGFR mutation
in stage I patients may be a favorable prognostic biomarker [32].
These driver genes may therefore be used as predictive biomarkers
if special compounds target these genes are found.
Our results may be slightly skewed due to the very low variation
rate of most of the genes examined, the small sample size of some
subgroups, the different detection methods, the different sample
sizes of different genes, and the repeated analysis of the same
specimens for different genes. As all patient specimens are truly
precious, a high-throughput method for detecting driver gene
alterations needs to be established as soon as possible.
In summary, our study demonstrates that subtypes of NSCLC
defined by histology and smoking status appear to be distinct
pathological entities with specific driver gene alterations and could
be considered different diseases. Patients with infrequent alter-
ations of driver genes implied that these are rare or orphan
diseases that should be treated from a different point of view in the
future. Features of characterized subgroups may help to select
patients with specific driver gene alterations for future clinical trials
and individualized therapy studies.
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